innovation in drug development processes - cde themed call launch 25 june 2013
DESCRIPTION
Presentation slides from CDE themed call launch event on 25 June - for full details of this call see: http://www.science.mod.uk/events/event_detail.aspx?eventid=259TRANSCRIPT
![Page 1: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/1.jpg)
Innovation in Drug Development Processes
Centre for Defence Enterprise
![Page 2: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/2.jpg)
Rapid technological change
![Page 3: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/3.jpg)
© Crown Copyright MOD 2011
The aim of CDE
![Page 4: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/4.jpg)
© Crown Copyright MOD 2011
Prove the value of novel, high-risk, high-potential-benefit research
![Page 5: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/5.jpg)
© Crown Copyright MOD 2011
Cost-effective military capability advantage
![Page 6: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/6.jpg)
25 June 2013
Five key operating principles underpin the CDE model
![Page 7: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/7.jpg)
Engaging innovators
![Page 8: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/8.jpg)
25 June 2013
Accessible opportunity
![Page 9: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/9.jpg)
Sustaining incentives
![Page 10: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/10.jpg)
Minimising participation costs
![Page 11: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/11.jpg)
Compliance
![Page 12: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/12.jpg)
Two routes to funding
![Page 13: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/13.jpg)
Online bid submission
![Page 14: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/14.jpg)
Intellectual property
![Page 15: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/15.jpg)
Themed calls
![Page 16: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/16.jpg)
CDE themed call programme
Countering insider threat attacks Call closes 27 Jun 2013
Secure communications Call closes 22 Aug 2013
Innovation in drug development processes
Call closes 29 Aug 2013
Enhancing military medical training and support for the medic
Call launch 16 July 2013 (Birmingham)
Novel solutions for emulating ship signatures (counter mine)
Call launch 23 July 2013 (Webinar)
Register and further details at www.science.mod.uk under ‘Events and Calls’
All call close at 17:00 hrs
![Page 17: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/17.jpg)
Defence Open Call
![Page 18: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/18.jpg)
Seeking the exceptional
![Page 19: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/19.jpg)
Challenging conventions
![Page 20: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/20.jpg)
4419 proposals received
![Page 21: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/21.jpg)
17% proposals funded
![Page 22: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/22.jpg)
£39M contracts awarded
![Page 23: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/23.jpg)
Exemplar project
![Page 24: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/24.jpg)
Fuel efficiency
![Page 25: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/25.jpg)
‘Micro generators’
![Page 26: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/26.jpg)
© Crown Copyright MOD 2011
Effective proposals
![Page 27: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/27.jpg)
Challenge, pace & exploitation
![Page 28: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/28.jpg)
The future of CDE
![Page 29: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/29.jpg)
Network and question
![Page 31: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/31.jpg)
© Crown copyright 2013 Dstl
25 June 2013
![Page 32: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/32.jpg)
An Introduction to CBR Science and Technology
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 33: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/33.jpg)
Chemical, Biological, Radiological
VISION Maximise the impact of science and technology (S&T) in
realising the UK policy aim of maintaining our political and
military freedom of action despite the presence, threat, or use
of chemical, biological or radiological weapons.
SDSR: NATIONAL SECURITY TASKS & PLANNING
GUIDELINES:
We will .. tackle those who threaten the UK & our interests,
including maintenance of underpinning technical expertise in key
areas. To deliver this we require …
Retention of our CBRN science and technology capabilities that
contribute to counter-proliferation and our response to the
potential use of such materials by terrorist or state actors.
NATIONAL SECURITY STRATEGY: RISKS
Tier 1 : International terrorism including the use of CBRN
materials
Tier 2 : Attack on the UK or its Territories by a state or proxy
using CBRN weapons.
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 34: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/34.jpg)
• Strategic objectives
– SUPPORT 3 Model Block (MB)
acquisitions
• More tech watch type activity. Less
development activity in research
programme
– INCREASE the amount of speculative,
high-risk, high-reward research.
• Emphasis on scientific quality and
innovation.
• Pause mature research
25 June 2013
Context
© Crown copyright 2013 Dstl
F12/13 F13/14
Threat 6.4M 6.1M
Inform 7.9M 7.1M
Prot Measures 14.9M 14.2M
Strat Facilities 6.2M 6.4M
£35.4M £33.8M
CBR research programme funding
UNCLASSIFIED
![Page 35: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/35.jpg)
Sense
Knowledge
Management Physical
Hazard
Management
Medical
Countermeasures
Hazard
Assessment
Operational
Analysis
Counter
Proliferation
Duty Of Care
CBR Inform
(MOD & Industry)
CBR Protective Measures
(International
Collaboration)
CBR Threat Reduction
(Cross Government)
CBR S&T
Programme
Prevention
of Supply
Protection Elimination
Arms
Control Disablement
Deterrence
Programme structure
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 36: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/36.jpg)
Programme and Delivery Directorate
CBR programme Other programmes
Dstl Depts Industry Academia
S&T Requirements
Partners
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 37: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/37.jpg)
Working across government
• Aim: programme coherency and mutual benefit from shared investments
• Number of other government departments with interest/requirement for CBRN S&T advice
• Different exploitation routes, similar fundamental requirements
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 38: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/38.jpg)
Impact of S&T
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 39: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/39.jpg)
Exploitation of S&T and where industry is involved
Early Innovation
Proof of concept
Assessment
Tech transfer Into service
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 40: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/40.jpg)
Alternative model
N2
Sample
Inlet to Detector
Capability
Research exploitation
Non-MOD markets
Rapid
Adaptation
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 41: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/41.jpg)
CBRN PROTECTION RESEARCH GOAL 9 – Medical Countermeasures
• Explore technology options to upkeep, update and upgrade the CBRN medical countermeasures capability. • To prevent individuals from experiencing the physiological effects of exposure to CBRN agents by the use of medical countermeasures, in order to maintain operational effectiveness on operations. • To move towards a post-exposure treatment posture while maintaining the current pre-exposure capability.
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 42: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/42.jpg)
Desired outcome: Strategic approach
• Where practicable all future medical
countermeasures (MedCM) should be
licensed (ie possess a Marketing
Authorisation in the UK).
• Broad-spectrum MedCM: provide protection
against more than one agent.
25 June 2013
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 43: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/43.jpg)
Programme aim
• MOD long-term aim: broad-spectrum
post-exposure therapies
• Allow a flexible response to current
and emerging threats
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 44: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/44.jpg)
BW MedCM strategy
Pre-exposure therapies
• Devise vaccines against biological agents
Post-exposure therapies
• BW-specific post-exposure therapies
• Broad-spectrum therapies
Lessens the need to pre-define the threat
spectrum
Delivery is dependent on collaboration
Ris
k
30%
70%
UNCLASSIFIED 25 June 2013
© Crown copyright 2013
Dstl
![Page 45: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/45.jpg)
A technical challenge
• The challenge of devising broad-spectrum MedCM is significant
– very challenging technical aspiration
• Incentivising industry to engage with MOD is difficult in this area
• Few incentives to develop broad-spectrum therapies
– Profit is in specific therapies for chronic diseases
• Low investment means there are very few broad-spectrum antibiotics in the pipeline
UNCLASSIFIED © Crown copyright 2013
Dstl
25 June 2013
![Page 46: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/46.jpg)
Summary • The CBR research programme is designed to maximise the
impact of science & technology in realising the UK policy aim of
maintaining our political and military freedom of action despite
the presence, threat, or use of chemical, biological or radiological
weapons.
• Broad-spectrum medical countermeasures are mechanism to
achieve this
• This CDE themed call is aimed to help identify future medical
countermeasures
25 June 2013
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 47: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/47.jpg)
CDE Themed Call:
Innovation in Drug Development
Processes
© Crown copyright 2013 Dstl
25 June 2013
UNCLASSIFIED
![Page 48: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/48.jpg)
CDE call: Innovation in Drug Development Processes
Aims to stimulate the development of antibacterial drug
development processes…
• benefiting the antibacterial development industry
• supporting the UK’s defence and security needs
UNCLASSIFIED 25 June 2013
© Crown copyright 2013
Dstl
![Page 49: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/49.jpg)
• Research proposals for this CDE themed call will also
be assessed by representatives from Dstl’s
collaborators in US Government, the Defence Threat
Reduction Agency (DTRA) and a selection of UK
based University academics.
• The US/academia will not be funding any of the
proposals resulting from this CDE call – funding will
only be from Dstl.
© Crown copyright 2013 Dstl
25 June 2013
CDE call: Innovation in Drug Development Processes
UNCLASSIFIED
![Page 50: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/50.jpg)
© Crown copyright 2013 Dstl
25 June 2013
![Page 51: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/51.jpg)
Innovations in Drug
Development Processes
25 June 2013
© Crown copyright 2013 Dstl UNCLASSIFIED
![Page 52: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/52.jpg)
Overview
• Background: target identification at Dstl
• CDE call: improving target exploitation
UNCLASSIFIED 25 June 2013
© Crown copyright 2013 Dstl
![Page 53: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/53.jpg)
25 June 2013
© Crown copyright 2013 Dstl
Broad-spectrum antibacterials
In order to support the development of novel antibiotics
by industry, MOD funds research to identify and validate
broad-spectrum antibacterial targets
Bacillus
anthracis
Burkholderia
pseudomallei /
mallei
Yersinia
pestis
Francisella
tularensis Coxiella
burnetii Brucella spp
UNCLASSIFIED
![Page 54: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/54.jpg)
Dstl’s key capabilities
25 June 2013
Animal models
Genetic manipulation of pathogens
In vitro models of infection
Cytoplasmic
membrane
Cell
wall
Capsule
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 55: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/55.jpg)
25 June 2013
• Target selection Identification
• Biological evaluation of target
• Down-selection Characterisation and
validation
• Collaborations
• Evaluation of novel technologies for inhibitor selection
Exploitation
Approach to antibacterial targets
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 56: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/56.jpg)
Target identification
• Whole genome approaches – Using high-throughput sequencing
technology
• Bioinformatics – Database of Essential Genes
– Pathogen vs non-pathogens
• Computational systems
biology – Mathematical modelling
25 June 2013
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 57: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/57.jpg)
Target characterisation and validation
• Genetic characterisation
– Development and construction of targeted mutants
– In vitro & in vivo evaluation
• Virulence
• Essential
• Biochemical characterisation – Protein engineering
– X-ray crystallography
25 June 2013
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 58: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/58.jpg)
Target exploitation
• Engagement with academia and/or industry
Currently:
– Target protein structures
– Assay development
– Inhibitor screening (proof-of-concept)
Future:
– Inhibitor screening & lead molecule
development
25 June 2013
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 59: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/59.jpg)
25 June 2013
Aspiration
– Enable development of broad-spectrum
antibacterials
– Engage with academic/industrial partners at an
early stage
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 60: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/60.jpg)
25 June 2013
CDE call Innovation in Drug Development Processes
Aims to stimulate the development of antibacterial drug
development processes…
• benefiting the antibacterial development industry
• supporting the UK’s defence and security needs
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 61: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/61.jpg)
Target-based antibacterial discovery
25 June 2013
Target identification
High throughput
screening or alternative
approach
Inhibitor identification
Lead inhibitor optimisation
(PK, distribution, toxicity, etc)
Structure-based drug
design
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 62: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/62.jpg)
25 June 2013
Challenge 1: Specific target inhibitor
identification
• eg
– decreasing propensity for resistance acquisition
– increasing hit rate
Technologies that improve the robustness of inhibitors identified for targets by HTS or other
approaches
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 63: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/63.jpg)
25 June 2013
Challenge 2: Improving structure-
based drug design
• eg
– reducing the time taken to produce high-resolution
target structures
– increasing robustness of in silico small molecule
design
Technologies that improve the process of structure-based drug design of antibacterials
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 64: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/64.jpg)
25 June 2013
Challenge 3: Potency for intracellular
pathogens
• eg
– altering physiochemical properties of inhibitors to
enhance uptake
– coupling inhibitors to other molecules to increase
intracellular retention
Technologies that improve the uptake of antibacterials into target cells and/or reduce efflux
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 65: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/65.jpg)
25 June 2013
What we WANT
• Proof-of-concept proposals
• Highly innovative approaches, tools, technologies
• Applicability to broad-spectrum targets
• Applicability to intracellular bacteria
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 66: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/66.jpg)
25 June 2013
What we DONT WANT
• Existing technologies
• Target identification
• Target-specific approaches
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 67: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/67.jpg)
25 June 2013
Proposals
• Proof of concept
• Value: no cap but likely £20-80K
• Duration: typically 3-9 months; to be completed by September
2014
• Call closes: 29 August 2013 at 1700 hrs
• Contract placement to be initiated from October 2013
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 68: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/68.jpg)
25 June 2013
Enquiries
• Technical enquiries: [email protected]
• General enquiries: [email protected]
+44 (0)1235 438445
UNCLASSIFIED © Crown copyright 2013
Dstl
![Page 69: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/69.jpg)
© Crown copyright 2013 Dstl
25 June 2013
![Page 70: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/70.jpg)
Crown Copyright (c) 2012
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
UNCLASSIFIED / FOR PUBLIC RELEASE
Centre for Defence Enterprise Submitting a Successful Proposal
Centre for Defence Enterprise (CDE)
![Page 71: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/71.jpg)
Maximising your chances
![Page 72: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/72.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Know what is available
![Page 73: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/73.jpg)
![Page 74: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/74.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Know what is available
![Page 75: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/75.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Know what is available
![Page 76: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/76.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Read available
information
Start with –
Quick Start Guide
plus other CDE manuals –
Account Manual, User
Manual, Technology
Application Manual
Know what is available
![Page 77: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/77.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Know what is available
![Page 78: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/78.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Developing a CDE proposal
![Page 79: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/79.jpg)
Dstl is part of the
Ministry of Defence
Value from technology
Innovative concept
Future capability
Proof of
concept Incremental development
![Page 80: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/80.jpg)
The essentials
![Page 81: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/81.jpg)
Description
![Page 82: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/82.jpg)
mins
Assessment
![Page 83: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/83.jpg)
Not an exam
![Page 84: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/84.jpg)
MOD Performance Assessment Framework
Five criteria:
Operational relevance
Likelihood of exploitation
Builds critical S&T capability to meet UK needs
Scientific quality/innovation
Science, innovation and technology risk
![Page 85: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/85.jpg)
Commercial tab
![Page 86: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/86.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Government-furnished X
![Page 87: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/87.jpg)
Health and safety
![Page 88: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/88.jpg)
Ethics
![Page 89: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/89.jpg)
Unclassified
![Page 90: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/90.jpg)
Crown Copyright (c) 2012
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
UNCLASSIFIED / FOR PUBLIC RELEASE
Proposal health check
![Page 91: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/91.jpg)
Claim of future benefit
![Page 92: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/92.jpg)
Contribution to future benefit
![Page 93: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/93.jpg)
Logical programme of work
![Page 94: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/94.jpg)
Generation of evidence
![Page 95: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/95.jpg)
Demonstration of progress
![Page 96: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/96.jpg)
Crown Copyright (c) 2012
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
UNCLASSIFIED / FOR PUBLIC RELEASE
Based on a claim of future benefit
Contribution to realisation of future benefit
Logical programme of work
Evidential outcomes
Demonstration of progress towards goal
Health check
![Page 97: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/97.jpg)
Early birds
![Page 98: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/98.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
This call closes:
17:00 hrs on
Thursday 29 August 2013
Deadline
![Page 99: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/99.jpg)
Crown Copyright (c) 2012
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
UNCLASSIFIED / FOR PUBLIC RELEASE
Centre for Defence Enterprise
www.science.mod.uk/enterprise
Call process queries
![Page 100: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/100.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
Call technical queries
![Page 101: Innovation in drug development processes - CDE themed call launch 25 June 2013](https://reader034.vdocuments.net/reader034/viewer/2022042714/54b703324a7959943a8b463c/html5/thumbnails/101.jpg)
Dstl is part of the
Ministry of Defence
UNCLASSIFIED / For Public Release
Centre for Defence Enterprise
www.science.mod.uk/enterprise [email protected]
Crown Copyright Dstl 2012
www.science.mod.uk
Events and Calls > Current calls for proposals > Innovation in drug
development processes
Further information